- In January 2024, Vanda Pharmaceuticals received FDA approval for an Investigational New Drug (IND) application to evaluate VTR‑297, a novel topical antifungal candidate for treating onychomycosis. This approval supports early-stage clinical testing of a potentially innovative treatment option for nail fungus infection
- In December 2023, Aurobindo Pharma (via Eugia Pharma Specialities Ltd.) secured USFDA final approval for a 300 mg/16.7 mL Posaconazole injection, a generic equivalent of Merck’s Noxafil. The product, aimed at preventing serious invasive Aspergillus and Candida infections in immunocompromised patients, targets an estimated market size of USD 25.4 million
- In September 2022, BDR Pharmaceuticals launched Zisavel (isavuconazole) capsules—a generic antifungal for treating invasive aspergillosis and mucormycosis—priced at approximately one-third the cost of existing therapies, improving accessibility in fungal infection management
- In March 2024, Akanocure Pharmaceuticals received Bayer’s “Grants4Ag” Award to support the development of novel antifungal agents intended for crop protection. The backing includes funding, mentoring, and testing resources to drive agricultural fungicide innovation
